Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects[1].
Medroxalol (0.1-10 μM; 20 min) shows α- and β-adrenergic receptor antagonism in isolated rabbit aortic strip[1].
Cell Viability Assay[1]
| Cell Line: | Isolated rabbit aortic strip |
| Concentration: | 0.1-10 μM |
| Incubation Time: | 20 min |
| Result: | Showed pA2 values of 6.09 and 7.73 for α-adrenergic receptors and β-adrenergic receptors, respevtively. |
Medroxalol (oral gavage; 12.5-50 mg/kg; once daily; 12 d) treatment shows antihypertensive activity in spontaneously hypertensive rats[1].
| Animal Model: | Male spontaneously hypertensive rats (SHR)[1] |
| Dosage: | 12.5, 25, or 50 mg/kg |
| Administration: | Oral gavage; 12.5, 25, or 50 mg/kg; once daily; 12 days |
| Result: | Produced a dose-related fall in blood pressure. |